HUP0301276A2 - Kombinációs terápia ösztrogénérzékeny betegségek kezelésére - Google Patents

Kombinációs terápia ösztrogénérzékeny betegségek kezelésére

Info

Publication number
HUP0301276A2
HUP0301276A2 HU0301276A HUP0301276A HUP0301276A2 HU P0301276 A2 HUP0301276 A2 HU P0301276A2 HU 0301276 A HU0301276 A HU 0301276A HU P0301276 A HUP0301276 A HU P0301276A HU P0301276 A2 HUP0301276 A2 HU P0301276A2
Authority
HU
Hungary
Prior art keywords
treatment
estrogen
combination therapy
sensitive disease
sensitive
Prior art date
Application number
HU0301276A
Other languages
English (en)
Inventor
Peter Langecker
S. Mark Moran
Original Assignee
Biomedicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedicines, Inc. filed Critical Biomedicines, Inc.
Publication of HUP0301276A2 publication Critical patent/HUP0301276A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány az ösztrogénérzékeny betegségek, mint pl. a mellrákkezelésére szolgáló gyógyszer-kombinációs terápiák hatékonyságátnövelő módszerekre, valamint az ilyen betegségek kezelésére alkalmasúj kombinációkra vonatkozik. Ó
HU0301276A 2000-10-06 2001-10-03 Kombinációs terápia ösztrogénérzékeny betegségek kezelésére HUP0301276A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23877200P 2000-10-06 2000-10-06
PCT/US2001/031060 WO2002030429A1 (en) 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease

Publications (1)

Publication Number Publication Date
HUP0301276A2 true HUP0301276A2 (hu) 2003-11-28

Family

ID=22899242

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301276A HUP0301276A2 (hu) 2000-10-06 2001-10-03 Kombinációs terápia ösztrogénérzékeny betegségek kezelésére

Country Status (14)

Country Link
US (5) US20020119502A1 (hu)
EP (1) EP1330251A4 (hu)
JP (1) JP2004510994A (hu)
CN (1) CN1471400A (hu)
AU (1) AU2001296578A1 (hu)
BR (1) BR0114655A (hu)
CA (1) CA2424299A1 (hu)
HU (1) HUP0301276A2 (hu)
IL (1) IL155237A0 (hu)
MX (1) MXPA03003032A (hu)
NZ (1) NZ525105A (hu)
PL (1) PL361874A1 (hu)
RU (1) RU2003112974A (hu)
WO (1) WO2002030429A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219617T2 (de) * 2001-05-16 2008-01-03 Novartis Ag Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
JP5777163B2 (ja) * 2009-07-03 2015-09-09 国立研究開発法人理化学研究所 Ｐｅｔ用標識化合物
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
WO2017093776A1 (en) * 2015-11-30 2017-06-08 Pharnext Method for adapting doses of combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
IE62715B1 (en) * 1989-03-10 1995-02-22 Endorecherche Inc Combination therapy for treatment of estrogen sensitive diseases
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites

Also Published As

Publication number Publication date
US20050130945A1 (en) 2005-06-16
PL361874A1 (en) 2004-10-04
AU2001296578A1 (en) 2002-04-22
WO2002030429A1 (en) 2002-04-18
NZ525105A (en) 2004-10-29
MXPA03003032A (es) 2003-06-06
CN1471400A (zh) 2004-01-28
US20050228053A1 (en) 2005-10-13
RU2003112974A (ru) 2004-11-27
IL155237A0 (en) 2003-11-23
EP1330251A1 (en) 2003-07-30
EP1330251A4 (en) 2006-03-15
CA2424299A1 (en) 2002-04-18
JP2004510994A (ja) 2004-04-08
US20050176691A1 (en) 2005-08-11
BR0114655A (pt) 2004-02-10
US20050232862A1 (en) 2005-10-20
US20020119502A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
DE50310516D1 (de) Fredericamycin-derivate
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
NO20022065D0 (no) Terapeutisk anvendelse
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EA200801425A1 (ru) Диазепиноны
SE0300098D0 (sv) Use of cyclin D1 inhibitors
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
HUP0303649A2 (hu) Mátrix-metalloproteináz-inhibitorok liposzómás célzása
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
BR0302590A (pt) Agente para tratamento de tumores sólidos
TW200626566A (en) 4, 7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses
ECSP003590A (es) Compuestos calcioliticos
SE0002739D0 (sv) New use
ATE386029T1 (de) Urokinase-inhibitoren
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.